Making up for scrapped IPO, melanoma diagnostics company DermTech raising $20M
DermTech has a biopsy-free approach to test for melanoma - using an adhesive patch to collect skin cells and test if the RNA expression is consistent with cancer.
After withdrawing IPO, DermTech raises $2.4M for its RNA-based, biopsy-free melanoma diagnostic
San Diego skin cancer diagnostics startup DermTech is developing gene classifiers and expression tests to help more accurately screen for dermatologic issues. It just raised $2.4 million to do so, according to a regulatory filing – an interesting funding notice, given its announcement last year that it was readying for – and then withdrawing – a $25 […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.